Description

Retatrutide is widely recognized as a “triple agonist” or “triple G” drug. Unlike earlier generation medications, it simultaneously targets three distinct metabolic hormone receptors:
• GLP-1 (Glucagon-like peptide-1): Increases feelings of fullness, slows down gastric emptying, and prompts insulin release.
• GIP (Glucose-dependent insulinotropic polypeptide): Synergizes with GLP-1 to suppress appetite and improve how the body processes glucose.
• Glucagon Receptor: Enhances energy expenditure and accelerates the breakdown of fat. This specific action sets it apart from existing medications like semaglutide or tirzepatide